174 related articles for article (PubMed ID: 7917544)
1. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA
Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544
[TBL] [Abstract][Full Text] [Related]
2. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
[TBL] [Abstract][Full Text] [Related]
3. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.
Bedford P; Fichtinger-Schepman AM; Shellard SA; Walker MC; Masters JR; Hill BT
Cancer Res; 1988 Jun; 48(11):3019-24. PubMed ID: 3365691
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
Shellard SA; Hosking LK; Hill BT
Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
[TBL] [Abstract][Full Text] [Related]
5. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines.
Hill BT; Shellard SA; Fichtinger-Schepman AM; Schmoll HJ; Harstrick A
Anticancer Drugs; 1994 Jun; 5(3):321-8. PubMed ID: 7919457
[TBL] [Abstract][Full Text] [Related]
6. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
7. DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR
Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754
[TBL] [Abstract][Full Text] [Related]
8. The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.
Blommaert FA; Floot BG; van Dijk-Knijnenburg HC; Berends F; Baan RA; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Chem Biol Interact; 1998 Jan; 108(3):209-25. PubMed ID: 9528691
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract][Full Text] [Related]
10. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells.
Blommaert FA; van Dijk-Knijnenburg HC; Dijt FJ; den Engelse L; Baan RA; Berends F; Fichtinger-Schepman AM
Biochemistry; 1995 Jul; 34(26):8474-80. PubMed ID: 7599137
[TBL] [Abstract][Full Text] [Related]
11. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
13. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
Hospers GA; de Vries EG; Mulder NH
Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
[TBL] [Abstract][Full Text] [Related]
14. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
Shellard SA; Fichtinger-Schepman AM; Lazo JS; Hill BT
Anticancer Drugs; 1993 Aug; 4(4):491-500. PubMed ID: 8400352
[TBL] [Abstract][Full Text] [Related]
15. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
16. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?
Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA
Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate.
Hill BT; Shellard SA; Hosking LK; Dempke WC; Fichtinger-Schepman AM; Tone T; Scanlon KJ; Whelan RD
Cancer Res; 1992 Jun; 52(11):3110-8. PubMed ID: 1591724
[TBL] [Abstract][Full Text] [Related]
20. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]